Navigation Links
Polaris Group Appoints Robert E. Hoffman as Chief Financial Officer
Date:3/15/2011

SAN DIEGO, March 15, 2011 /PRNewswire/ -- Polaris Group today announced the appointment of Robert E. Hoffman as chief financial officer.

Hoffman has joined Polaris from Arena Pharmaceuticals Inc., where he held senior financial positions for more than 13 years. Most recently, Hoffman was vice president of finance and chief financial officer. In his leadership roles, Hoffman contributed to the success of Arena's initial public offering in 2000 and other equity, debt and collaborative  transactions that totaled nearly $1.5 billion as Arena built a pipeline of drug candidates and completed a Phase 3 pivotal program for its lead candidate.

"Robert brings extensive financial management experience from a public, late-stage development company to Polaris Group at a pivotal time," said Bor-Wen Wu, Ph.D., president and chief executive officer of Polaris Group. "We are moving our lead project, ADI-PEG 20, into a Phase 3 trial in hepatocellular carcinoma as well as advancing multiple Phase 2 trials in other cancer types. In line with our clinical progress, we are expanding our management team as Polaris transforms into a late-stage clinical development company."

Hoffman currently serves as a member of the Financial Accounting Standards Board's small business advisory committee and the steering committee of the Association of Bioscience Financial Officers. In addition, he is a member and former president of the San Diego chapter of Financial Executives International and a director of the charitable organization Day For Change. Hoffman earned a bachelor's degree in business administration from St. Bonaventure University.

"I am excited about the opportunity to participate in Polaris' transformation into a late-stage company," said Hoffman. "Lead project ADI-PEG 20 represents a significant opportunity in the treatment of many cancer types. I look forward to working with the Polaris team to advance this promising drug candidate through its final stages of clinical development."  

About ADI-PEG 20A key metabolic difference between some cancer cells and healthy cells is their dependence on the external supply of certain amino acids for survival and growth. ADI-PEG 20 is a pegylated form of arginine deiminase, an enzyme that depletes circulating arginine, which suppresses tumor cell growth while leaving healthy cells unharmed. ADI-PEG 20 has completed Phase 2 clinical trials in hepatocellular carcinoma (HCC) and in metastatic melanoma and is currently being investigated in Phase 2 trials in small cell lung cancer and in mesothelioma patients.

About Polaris GroupPolaris Group is a privately held, multinational biopharmaceutical company that specializes in the research and development of protein drugs to treat cancer and other debilitating diseases. The company's lead therapeutic, ADI-PEG 20, is advancing into a pivotal Phase 3 trial for hepatocellular carcinoma. Polaris is also investigating ADI-PEG 20 as a treatment for other arginine-dependent cancers, such as prostate cancer, leukemia, lymphoma, sarcoma and pancreatic cancer. In addition to the ADI-PEG 20 project, Polaris is researching and developing other biotherapeutic agents and has a small molecule drug program that utilizes rational structure-based approach to design novel compounds that inhibit the biological function of cancer-related protein targets.

For additional information please visit www.polarispharma.comMedia Contacts:Heidi Chokeir, Ph.D.Russo Partners(619) 528-2217(858) 380-6584heidi.chokeir@russopartnersllc.comJohn Bomalaski, M.D.Polaris Group(858) 452-6688, ext. 114jbomalaski@polarispharma.com
'/>"/>

SOURCE Polaris Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Home Medical Equipment Group Supports Bipartisan Bill to Repeal the Controversial Medicare Competitive Bidding Program for Homecare
2. Southern Home Medical Equipment Engages Northern Virginia Based Waterford Holdings Group to Evaluate and Consider Acquisition Candidates in the Mid-Atlantic Area
3. LaVoie Group Wins Gold Mercury Award For Medical Device Company, Alphatec Spine
4. LaVoie Group Wins Two Mercury Excellence Awards
5. Sinovac Reports Positive Preliminary Phase I Clinical Trial Results for EV71 Vaccine in Adult Group
6. Software Development Firms New Intellectual Property Group, Blue Horseshoe IP Creates Solutions to Help Customers Optimize Supply Chain
7. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results
8. Rottenstein Law Group Applauds New Efforts of U.S. FDA to Look More Carefully at Metal-on-Metal Implants After DePuy Recall
9. PCMA: Anti-Fraud Group Spotlights Policies that Promote Health Care Fraud and Abuse
10. New Image Global, Inc. Partners With Limbs For U, Charitable Service Group to Provide Prosthetic Limbs in the Dominican Republic
11. Deb Group Introduces First Real-time Hand Hygiene Group Monitoring System Based on World Health Organization Guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Consumers have taken a more ... placed more emphasis on patient outcomes. ... in the pharmaceutical industry have evolved beyond just ... companies are focusing on becoming more patient-oriented across ... and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from PsychTests.com reveals that behind the tendency to ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
Breaking Medicine News(10 mins):